Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activations and Closures

ACTIVATED: OV.18/ICON6: A Randomized Phase III Study of Concurrent Cediranib (AZD2171) with Platinum-Based Chemotherapy and Maintenance Cediranib (AZD2171) in Women with Platinum-Sensitive Relapsed Ovarian Cancer was centrally activated 2 April 2008.

ACTIVATED: BI.1: A Phase III Study of Gemcitabine Plus Capecitabine (GEMCAP) versus Gemcitabine Alone in Advanced Biliary Cancer was centrally activated 19 March 2008.

ACTIVATED: PR.12: A Phase III Study of Neoadjuvant Docetaxel and Androgen Suppression Plus Radiation Therapy Versus Androgen Suppression Alone Plus Radiation Therapy for High-Risk Localized Adenocarcinoma of the Prostate (DART) was centrally activated 3 March 2008.

ACTIVATED; CRC.5 (CALGB 80405): A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum was centrally activated 3 March 2008.

CLOSED TO ACCRUAL: HN.5: A Phase I Study of Adjuvant OSI-774 (Tarceva ) in Patients Following Combined Chemo-Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck was closed to accrual 31 March 2008.

CLOSED TO ACCRUAL: IND.166B: A phase I Study of AEG35156 Given as a 2-Hour Intravenous Infusion in Combination with Docetaxel in Patients with Solid Tumours completed accrual and was closed permanently 20 March 2008.

CLOSED TO ACCRUAL: MY.11: A randomized Phase II Dose Finding Study of Lenalidomide and Melphalan in Patients with Previously Untreated Multiple Myeloma was closed 27 March 2008.

CLOSED TO ACCRUAL: IND.185: A Phase II Study of Sunitinib in Patients with Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma was closed to accrual as of 17 April 2008.

CLOSED TO ACCRUAL: BR.25: A Phase II Study of Hypofractionated 3-Dimensional Conformal Radiotherapy (3DCRT) for Inoperable Stage I/II Non-Small Cell Lung Cancer (NSCLC)was closed to accrual 18 April 2008.